Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 51

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 51
---
;                                                                                                                                |
| ● | the                                                                                                                                    
 risk that the Merger might not be consummated in a timely manner or at all and the potential adverse effect of the public announcement 
 of the Merger or delay or failure to complete the Merger on the reputation of TELO;                                                    |
| ● | the                                                                                                                                    
 likely detrimental effect on TELO’s cash position, stock price and ability to initiate another process and to successfully             
 complete an alternative transaction should the Merger not be completed;                                                                |
| ● | the                                                                                                                                    
 risk to TELO’s business, operations and financial results in the event that the Merger is not consummated, including the diminution    
 of TELO’s cash and the significant challenges associated with the need to raise additional capital through the public or private       
 sale of equity securities;                                                                                                             |
| ● | the evaluation of alternative transactions (including                                                                                  
 capital raising, partnerships); and                                                                                                    |
| ● | various                                                                                                                                
 other risks associated with the combined company and the Merger, including those described in the section titled “Risk Factors.”       |

Neither TELO nor the Board considered other merger candidates. TELO’s CEO was previously familiar with TELI and its prospects for growth and was interested in acquiring this specific company to increase shareholder value.

In view of the wide variety of reasons considered in connection with its evaluation of the Merger and the complexity of these matters, the TELO Board did not find it useful to attempt, and did not attempt, to quantify, rank or otherwise assign relative weights to these reasons. In considering the reasons described above, individual members of the TELO Board may have given different weight to different reasons. The TELO Board conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, TELO’s CEO and the legal and financial advisors of TELO, and considered the reasons overall to be favorable to, and to support, its determination.

On October 15, 2025, TELO provided Moore with additional responses and supplementary material to support its forecasts.

The LOI was signed by both TELO and TELI on October 17, 2025.

At no point did TELO and TELI enter into a non-disclosure agreement that contained any don’t ask, don’t waive standstill provisions.

On November 10, 2025, Moore provided TELO’s and TELI’s management with a fairness opinion for the Exchange Ratio and valuation reports of TELO and TELI.

On November 10